Safety and Efficacy of Mirazid for Schistosomiasis Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Schistosoma Hematobium InfectionSchistosomiasis Mansoni
Interventions
DRUG

Myrrh

Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.

Trial Locations (2)

Unknown

Tanta Health Unit, Gharbiya

Health Unit of Atfeeh, Giza

Sponsors
All Listed Sponsors
lead

Pharco Pharmaceuticals

INDUSTRY